NCRNA combined therapy as future treatment option for cancer

Cornelia Braicu; Cristina Catana; George A. Calin; Ioana Berindan-Neagoe

doi:10.2174/1381612820666140826153529

NCRNA combined therapy as future treatment option for cancer

Cornelia Braicu, Cristina Catana, George A. Calin, Ioana Berindan-Neagoe

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Cancer initiation and progression are governed by a complex multistep process in which successive alterations accumulate in multiple protein-coding and noncoding genes. MicroRNAs are an evolutionarily conserved class of endogenous 19- to 24-nucleotide noncoding RNAs that have been validated as key players in the balance of most cellular processes, including drug resistance. MicroRNAs change the output of protein-coding genes through posttranscriptional regulation by binding in a sequence-specific manner to the transcripts of their target genes. Resistance to therapy remains a major challenge in cancer treatment; clear solutions to this problem have yet to be found, in spite of intensive research in recent years. In this review, we explore the concept of cancer multitherapy using noncoding RNAs. We also address basic scientific questions that are related to personalized cancer treatment.

Original language	English (US)
Pages (from-to)	6565-6574
Number of pages	10
Journal	Current pharmaceutical design
Volume	20
Issue number	42
DOIs	https://doi.org/10.2174/1381612820666140826153529
State	Published - Mar 1 2014

Keywords

Cancer
Multitherapy
Phytochemicals
ncRNA/miRNA

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.2174/1381612820666140826153529

Cite this

@article{e629051faa0847c5ae4709c6e0197ecb,

title = "NCRNA combined therapy as future treatment option for cancer",

abstract = "Cancer initiation and progression are governed by a complex multistep process in which successive alterations accumulate in multiple protein-coding and noncoding genes. MicroRNAs are an evolutionarily conserved class of endogenous 19- to 24-nucleotide noncoding RNAs that have been validated as key players in the balance of most cellular processes, including drug resistance. MicroRNAs change the output of protein-coding genes through posttranscriptional regulation by binding in a sequence-specific manner to the transcripts of their target genes. Resistance to therapy remains a major challenge in cancer treatment; clear solutions to this problem have yet to be found, in spite of intensive research in recent years. In this review, we explore the concept of cancer multitherapy using noncoding RNAs. We also address basic scientific questions that are related to personalized cancer treatment.",

keywords = "Cancer, Multitherapy, Phytochemicals, ncRNA/miRNA",

author = "Cornelia Braicu and Cristina Catana and Calin, {George A.} and Ioana Berindan-Neagoe",

note = "Publisher Copyright: {\textcopyright} 2014 Bentham Science Publishers.",

year = "2014",

month = mar,

day = "1",

doi = "10.2174/1381612820666140826153529",

language = "English (US)",

volume = "20",

pages = "6565--6574",

journal = "Current pharmaceutical design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "42",

}

TY - JOUR

T1 - NCRNA combined therapy as future treatment option for cancer

AU - Braicu, Cornelia

AU - Catana, Cristina

AU - Calin, George A.

AU - Berindan-Neagoe, Ioana

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Cancer initiation and progression are governed by a complex multistep process in which successive alterations accumulate in multiple protein-coding and noncoding genes. MicroRNAs are an evolutionarily conserved class of endogenous 19- to 24-nucleotide noncoding RNAs that have been validated as key players in the balance of most cellular processes, including drug resistance. MicroRNAs change the output of protein-coding genes through posttranscriptional regulation by binding in a sequence-specific manner to the transcripts of their target genes. Resistance to therapy remains a major challenge in cancer treatment; clear solutions to this problem have yet to be found, in spite of intensive research in recent years. In this review, we explore the concept of cancer multitherapy using noncoding RNAs. We also address basic scientific questions that are related to personalized cancer treatment.

AB - Cancer initiation and progression are governed by a complex multistep process in which successive alterations accumulate in multiple protein-coding and noncoding genes. MicroRNAs are an evolutionarily conserved class of endogenous 19- to 24-nucleotide noncoding RNAs that have been validated as key players in the balance of most cellular processes, including drug resistance. MicroRNAs change the output of protein-coding genes through posttranscriptional regulation by binding in a sequence-specific manner to the transcripts of their target genes. Resistance to therapy remains a major challenge in cancer treatment; clear solutions to this problem have yet to be found, in spite of intensive research in recent years. In this review, we explore the concept of cancer multitherapy using noncoding RNAs. We also address basic scientific questions that are related to personalized cancer treatment.

KW - Cancer

KW - Multitherapy

KW - Phytochemicals

KW - ncRNA/miRNA

UR - http://www.scopus.com/inward/record.url?scp=84911468290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911468290&partnerID=8YFLogxK

U2 - 10.2174/1381612820666140826153529

DO - 10.2174/1381612820666140826153529

M3 - Article

C2 - 25341933

AN - SCOPUS:84911468290

SN - 1381-6128

VL - 20

SP - 6565

EP - 6574

JO - Current pharmaceutical design

JF - Current pharmaceutical design

IS - 42

ER -

NCRNA combined therapy as future treatment option for cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this